Cullinan Therapeutics (CGEM) Current Assets (2020 - 2026)

Cullinan Therapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $361.4 million for Q1 2026.

• On a quarterly basis, Current Assets rose 13.73% year-over-year to $361.4 million in Q1 2026; TTM through Mar 2026 was $361.4 million, a 13.73% increase from a year earlier, with the FY2025 full-year figure at $386.8 million, down 6.73% from the prior year.
• Current Assets fell to $361.4 million in Q1 2026 per CGEM's latest filing, from $386.8 million in the prior quarter.
• Across five years, Current Assets topped out at $677.8 million in Q2 2024 and bottomed at $275.9 million in Q2 2025.
• The 5-year median for Current Assets is $445.7 million (2024), against an average of $451.2 million.
• Across the five-year window, Current Assets surged 80.81% in 2022 and tumbled 59.29% in 2025, its largest moves.
• Year by year, Current Assets stood at $474.5 million in 2022, then climbed by 1.21% to $480.2 million in 2023, then fell by 13.65% to $414.7 million in 2024, then slipped by 6.73% to $386.8 million in 2025, then slipped by 6.55% to $361.4 million in 2026.
• Per Business Quant, the three latest CGEM Current Assets figures stand at $361.4 million (Q1 2026), $386.8 million (Q4 2025), and $342.2 million (Q3 2025).